论文部分内容阅读
目的:研究严重败血症患者体内阿米卡星的药代动力学特点。方法:选取32例革兰阴性败血症患者,给予25mg·kg-1阿米卡星治疗,采用非房室模型处理分析阿米卡星在患者体内的药代动力学。结果:在32例革兰阴性败血症患者体内阿米卡星的药物分布平均值(0.36±0.05)L·kg-1,血液清除率平均值(3.88±0.98)m L·min-1·kg-1。且患者的肌酐清除率(CCr)和血清肌酸酐(SCr)的相关性在统计学上具有显著意义。结论:严重的败血症患者采用高剂量的阿米卡星(≥25mg·kg-1)治疗时,要考虑到患者与普通人群的药代动力学不同,考虑到败血症对其药代动力学的影响并及时检测其血药浓度的变化。
Objective: To study the pharmacokinetics of amikacin in patients with severe sepsis. Methods: Thirty-two patients with Gram-negative sepsis were treated with 25 mg · kg-1 amikacin. The pharmacokinetics of amikacin in patients were analyzed by non-compartmental model. Results: The average distribution of amikacin in 32 Gram-negative sepsis patients was (0.36 ± 0.05) L · kg-1, and the mean value of blood clearance was (3.88 ± 0.98) m L · min-1 · kg- 1. And the correlation between patient’s creatinine clearance (CCr) and serum creatinine (SCr) was statistically significant. Conclusions: Severe sepsis patients taking high dose of amikacin (≥25mg · kg-1) treatment, taking into account the patient and the general population pharmacokinetics, taking into account the impact of sepsis on its pharmacokinetics And timely detection of changes in blood concentration.